Microbot Medical said procedure volume on its LIBERTY Endovascular Robotic System rose 44% in the third quarter of 2026 compared with the second quarter, even as quarterly revenue fell to $72,000 from $241,000, the company disclosed alongside its Form 10-Q filing on November 16, 2026. The number of hospital and clinic accounts using the system grew to 12 from 10, and every customer that had exhausted its initial inventory placed a reorder for multiple systems, according to Microbot Medical.
The company ended the quarter with roughly $62 million in cash, cash equivalents, and marketable securities. It also signed a three-year exclusive distribution agreement with Medtechnica Ltd. covering Israel, with initial orders expected in the fourth quarter.
What does the LIBERTY robot actually do?
LIBERTY is an FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures — catheter-based interventions used to block blood flow to tumors or malformations without open surgery. It has been used for prostatic artery embolization, Y-90 radioembolization, genicular artery embolization, and uterine artery embolization. Rather than standing beside the patient and manually threading a catheter through blood vessels by feel, the physician operates LIBERTY from a console, which Microbot says reduces the physical strain and radiation exposure that interventional radiologists accumulate over a career of fluoroscopy-guided procedures.
Because LIBERTY ships as a single-use, disposable robotic catheter system rather than a capital piece of equipment physicians buy once, Microbot's revenue depends on repeat consumable orders rather than large upfront hardware sales — closer to a razor-and-blades model than to a one-time capital equipment sale.
Why did revenue fall while procedures rose?
Microbot attributed the revenue decline to the timing of customer reorders, summer seasonality, and the pace of hospital Value Analysis Committee reviews — the internal purchasing approval processes hospitals use before committing budget to new devices. Cost of goods sold rose 24% sequentially, partly from inventory write-downs, pushing the company's gross margin negative for the quarter even as manufacturing cost per unit continued to decline.
That combination — rising utilization, falling reported revenue — is common for early-commercial medical device companies selling consumables: a hospital's first order can be large relative to its actual monthly usage, so a quarter without a big reorder can look weak on paper even while the underlying number of procedures performed keeps climbing. Microbot's 100% reorder rate among customers who ran out of initial stock is the figure management is using to argue the underlying trend is positive, alongside new accounts added in North Carolina and the company's first customer in California.
What's next for Microbot?
The Israel distribution deal with Medtechnica marks Microbot's first confirmed international commercial channel outside the US, with initial orders expected before year-end. The company holds 44 issued patents and 49 pending applications across the US, Japan, China, and Canada, suggesting it is positioning LIBERTY for registration in additional markets beyond its current US base. With $62 million in cash on hand, Microbot has runway to keep expanding its account base, but the next several quarters of reorder volume — not just procedure counts — will determine whether its revenue trend turns consistently upward.